Abstract
Background: Cannabinoid has long been used for medicinal purposes. Cannabinoid signaling has been considered the therapeutic target for treating pain, addiction, obesity, inflammation, and other diseases. Recent studies have suggested that in addition to CB1 and CB2, there are non-CB1 and non-CB2 cannabinoid-related orphan GPCRs including GPR18, GPR55, and GPR119. In addition, CB1 and CB2 display allosteric binding and biased signaling, revealing correlations between biased signaling and functional outcomes. Interestingly, new investigations have indicated that CB1 is functionally present within the mitochondria of striated and heart muscles directly regulating intramitochondrial signaling and respiration.
Conclusion: In this review, we summarize the recent progress in cannabinoid-related orphan GPCRs, CB1/CB2 structure, Gi/Gs coupling, allosteric ligands and biased signaling, and mitochondria-localized CB1, and discuss the future promise of this research.
Keywords: Cannabinoid receptor, structure, orphan GPCRs, allosteric ligand, biased signaling, mitochondria.
Graphical Abstract
[1]
Adams, I.B.; Martin, B.R. Cannabis: Pharmacology and toxicology in animals and humans. Addiction, 1996, 91, 1585-1614.
[3]
Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev., 2006, 58, 389-462.
[4]
di Tomaso, E.; Beltramo, M.; Piomelli, D. Brain cannabinoids in chocolate. Nature, 1996, 382, 677-678.
[5]
Lambert, D.M.; Fowler, C.J. The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem., 2005, 48, 5059-5087.
[6]
Pineiro, R.; Falasca, M. Lysophosphatidylinositol signalling: New wine from an old bottle. Biochim. Biophys. Acta, 2012, 1821, 694-705.
[7]
Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346, 561-564.
[8]
Moro, O.; Lameh, J.; Hogger, P.; Sadee, W. Hydrophobic amino acid in the i2 loop plays a key role in receptor-G protein coupling. J. Biol. Chem., 1993, 268, 22273-22276.
[9]
Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
[10]
Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R.; Pertwee, R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 2002, 54, 161-202.
[11]
Bonz, A.; Laser, M.; Kullmer, S.; Kniesch, S.; Babin-Ebell, J.; Popp, V.; Ertl, G.; Wagner, J.A. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J. Cardiovasc. Pharmacol., 2003, 41, 657-664.
[12]
Feng, Z.; Alqarni, M.H.; Yang, P.; Tong, Q.; Chowdhury, A.; Wang, L.; Xie, X.Q. Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs. J. Chem. Inf. Model., 2014, 54, 2483-2499.
[13]
Brown, S.M.; Wager-Miller, J.; Mackie, K. Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim. Biophys. Acta, 2002, 1576, 255-264.
[14]
Chen, X.P.; Yang, W.; Fan, Y.; Luo, J.S.; Hong, K.; Wang, Z.; Yan, J.F.; Chen, X.; Lu, J.X.; Benovic, J.L.; Zhou, N.M. Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i). Br. J. Pharmacol., 2010, 161, 1817-1834.
[15]
Onaivi, E.S.; Ishiguro, H.; Gong, J.P.; Patel, S.; Perchuk, A.; Meozzi, P.A.; Myers, L.; Mora, Z.; Tagliaferro, P.; Gardner, E.; Brusco, A.; Akinshola, B.E.; Liu, Q.R.; Hope, B.; Iwasaki, S.; Arinami, T.; Teasenfitz, L.; Uhl, G.R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N. Y. Acad. Sci., 2006, 1074, 514-536.
[16]
Bab, I.; Zimmer, A. Cannabinoid receptors and the regulation of bone mass. Br. J. Pharmacol., 2008, 153, 182-188.
[18]
Bonhaus, D.W.; Chang, L.K.; Kwan, J.; Martin, G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther., 1998, 287, 884-888.
[19]
Calandra, B.; Portier, M.; Kerneis, A.; Delpech, M.; Carillon, C.; Le Fur, G.; Ferrara, P.; Shire, D. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur. J. Pharmacol., 1999, 374, 445-455.
[20]
Pertwee, R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. (Lond), 2006, 30(Suppl. 1), S13-S18.
[21]
Zheng, C.; Chen, L.; Chen, X.; He, X.; Yang, J.; Shi, Y.; Zhou, N. The second intracellular loop of the human cannabinoid CB2 receptor governs G protein coupling in coordination with the carboxyl terminal domain. PLoS One, 2013, 8e63262
[22]
Lu, Y.; Anderson, H.D. Cannabinoid signaling in health and disease. Cancer J. Physiol. Pharmacol, 2017, 95, 311-327.
[23]
Pavlopoulos, S.; Thakur, G.A.; Nikas, S.P.; Makriyannis, A. Cannabinoid receptors as therapeutic targets. Curr. Pharm. Des., 2006, 12, 1751-1769.
[24]
Lutz, B.; Marsicano, G.; Maldonado, R.; Hillard, C.J. The endocannabinoid system in guarding against fear, anxiety and stress. Nat. Rev. Neurosci., 2015, 16, 705-718.
[25]
Mbvundula, E.C.; Rainsford, K.D.; Bunning, R.A. Cannabinoids in pain and inflammation. Inflammopharmacology, 2004, 12, 99-114.
[26]
Guindon, J.; Hohmann, A.G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol., 2008, 153, 319-334.
[27]
Feng, R.; Milcarek, C.A.; Xie, X.Q. Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion. BMC Pharmacol. Toxicol., 2014, 15, 30.
[28]
Manglik, A.; Kruse, A.C. Structural Basis for G Protein-Coupled Receptor Activation. Biochemistry, 2017, 56, 5628-5634.
[29]
Manglik, A.; Kobilka, B.K.; Steyaert, J. Nanobodies to Study G Protein-Coupled Receptor Structure and Function. Annu. Rev. Pharmacol. Toxicol., 2017, 57, 19-37.
[30]
Hua, T.; Vemuri, K.; Pu, M.; Qu, L.; Han, G.W.; Wu, Y.; Zhao, S.; Shui, W.; Li, S.; Korde, A.; Laprairie, R.B.; Stahl, E.L.; Ho, J.H.; Zvonok, N.; Zhou, H.; Kufareva, I.; Wu, B.; Zhao, Q.; Hanson, M.A.; Bohn, L.M.; Makriyannis, A.; Stevens, R.C.; Liu, Z.J. Crystal structure of the human cannabinoid receptor CB1. Cell, 2016, 167(3), 750-762.e714.
[31]
Bertalovitz, A.C.; Ahn, K.H.; Kendall, D.A. Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1. Drug Dev. Res., 2010, 71, 404-411.
[32]
Fay, J.F.; Dunham, T.D.; Farrens, D.L. Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry, 2005, 44, 8757-8769.
[33]
Shao, Z.; Yin, J.; Chapman, K.; Grzemska, M.; Clark, L.; Wang, J.; Rosenbaum, D.M. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature, 2016, 540, 602-606.
[34]
Hua, T.; Vemuri, K.; Nikas, S.P.; Laprairie, R.B.; Wu, Y.; Qu, L.; Pu, M.; Korde, A.; Jiang, S.; Ho, J.H.; Han, G.W.; Ding, K.; Li, X.; Liu, H.; Hanson, M.A.; Zhao, S.; Bohn, L.M.; Makriyannis, A.; Stevens, R.C.; Liu, Z.J. Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature, 2017, 547, 468-471.
[35]
Isberg, V.; Mordalski, S.; Munk, C.; Rataj, K.; Harpsoe, K.; Hauser, A.S.; Vroling, B.; Bojarski, A.J.; Vriend, G.; Gloriam, D.E. GPCRdb: an information system for G protein-coupled receptors. Nucleic Acids Res., 2017, 45, 2936.
[36]
Song, Z.H.; Slowey, C.A.; Hurst, D.P.; Reggio, P.H. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol. Pharmacol., 1999, 56, 834-840.
[37]
Xie, X.Q.; Chen, J.Z.; Billings, E.M. 3D structural model of the G-protein-coupled cannabinoid CB2 receptor. Proteins, 2003, 53, 307-319.
[38]
Tuccinardi, T.; Ferrarini, P.L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. J. Med. Chem., 2006, 49, 984-994.
[39]
Stern, E.; Muccioli, G.G.; Millet, R.; Goossens, J.F.; Farce, A.; Chavatte, P.; Poupaert, J.H.; Lambert, D.M.; Depreux, P.; Henichart, J.P. Novel 4-oxo-1, 4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. J. Med. Chem., 2006, 49, 70-79.
[40]
Raduner, S.; Majewska, A.; Chen, J.Z.; Xie, X.Q.; Hamon, J.; Faller, B.; Altmann, K.H.; Gertsch, J. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J. Biol. Chem., 2006, 281, 14192-14206.
[41]
Latek, D.; Kolinski, M.; Ghoshdastider, U.; Debinski, A.; Bombolewski, R.; Plazinska, A.; Jozwiak, K.; Filipek, S. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic beta 2 AR. J. Mol. Model., 2011, 17, 2353-2366.
[42]
Yang, P.; Myint, K.Z.; Tong, Q.; Feng, R.; Cao, H.; Almehizia, A.A.; Alqarni, M.H.; Wang, L.; Bartlow, P.; Gao, Y.; Gertsch, J.; Teramachi, J.; Kurihara, N.; Roodman, G.D.; Cheng, T.; Xie, X.Q. Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors. J. Med. Chem., 2012, 55, 9973-9987.
[43]
Hu, J.; Feng, Z.; Ma, S.; Zhang, Y.; Tong, Q.; Alqarni, M.H.; Gou, X.; Xie, X.Q. Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery. J. Chem. Inf. Model., 2016, 56, 1152-1163.
[44]
Laschet, C.; Dupuis, N.; Hanson, J. The G protein-coupled receptors deorphanization landscape. Biochem. Pharmacol., 2018, 153, 62-74.
[46]
Mackie, K.; Stella, N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J., 2006, 8, E298-E306.
[47]
Irving, A.; Abdulrazzaq, G.; Chan, S.L.F.; Penman, J.; Harvey, J.; Alexander, S.P.H. Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. Adv. Pharmacol., 2017, 80, 223-247.
[48]
Overton, H.A.; Babbs, A.J.; Doel, S.M.; Fyfe, M.C.; Gardner, L.S.; Griffin, G.; Jackson, H.C.; Procter, M.J.; Rasamison, C.M.; Tang-Christensen, M.; Widdowson, P.S.; Williams, G.M.; Reynet, C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab., 2006, 3, 167-175.
[49]
Sawzdargo, M.; Nguyen, T.; Lee, D.K.; Lynch, K.R.; Cheng, R.; Heng, H.H.; George, S.R.; O’Dowd, B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res., 1999, 64, 193-198.
[50]
Brown A.J.,, W.A. Identification of modulators of GPR55 activity.
Assignee:GlaxoSmithKline 2001.Patent WO00186305.
[51]
Drmota, E, G.P.; Groblewski, T. Screening assays for cannabinoidligand
type modulators. Assignee: Astra Zeneca 2004.Patent WO2004074844.
[52]
Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun., 2007, 362, 928-934.
[53]
Anavi-Goffer, S.; Baillie, G.; Irving, A.J.; Gertsch, J.; Greig, I.R.; Pertwee, R.G.; Ross, R.A. Modulation of L-alpha-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem., 2012, 287, 91-104.
[54]
Henstridge, C.M.; Balenga, N.A.; Schroder, R.; Kargl, J.K.; Platzer, W.; Martini, L.; Arthur, S.; Penman, J.; Whistler, J.L.; Kostenis, E.; Waldhoer, M.; Irving, A.J. GPR55 ligands promote receptor coupling to multiple signalling pathways. Br. J. Pharmacol., 2010, 160, 604-614.
[55]
Lauckner, J.E.; Jensen, J.B.; Chen, H.Y.; Lu, H.C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA, 2008, 105, 2699-2704.
[56]
Henstridge, C.M.; Balenga, N.A.; Ford, L.A.; Ross, R.A.; Waldhoer, M.; Irving, A.J. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J., 2009, 23, 183-193.
[57]
Kotsikorou, E.; Sharir, H.; Shore, D.M.; Hurst, D.P.; Lynch, D.L.; Madrigal, K.E.; Heynen-Genel, S.; Milan, L.B.; Chung, T.D.; Seltzman, H.H.; Bai, Y.; Caron, M.G.; Barak, L.S.; Croatt, M.P.; Abood, M.E.; Reggio, P.H. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry, 2013, 52, 9456-9469.
[58]
Moreno, E.; Andradas, C.; Medrano, M.; Caffarel, M.M.; Perez-Gomez, E.; Blasco-Benito, S.; Gomez-Canas, M.; Pazos, M.R.; Irving, A.J.; Lluis, C.; Canela, E.I.; Fernandez-Ruiz, J.; Guzman, M.; McCormick, P.J.; Sanchez, C. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J. Biol. Chem., 2014, 289, 21960-21972.
[59]
Balenga, N.A.; Martinez-Pinilla, E.; Kargl, J.; Schroder, R.; Peinhaupt, M.; Platzer, W.; Balint, Z.; Zamarbide, M.; Dopeso-Reyes, I.G.; Ricobaraza, A.; Perez-Ortiz, J.M.; Kostenis, E.; Waldhoer, M.; Heinemann, A.; Franco, R. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling. Br. J. Pharmacol., 2014, 171, 5387-5406.
[60]
McHugh, D.; Page, J.; Dunn, E.; Bradshaw, H.B. Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br. J. Pharmacol., 2012, 165, 2414-2424.
[61]
Sheskin, T.; Hanus, L.; Slager, J.; Vogel, Z.; Mechoulam, R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem., 1997, 40, 659-667.
[62]
Jones, R.M. Discovery of agonists of the glucose dependent insulinotropic
receptor, GPR119, a pancre atic beta-cell oGPCR, for the
treatment of NIDDM. Drugs Future 31 (Suppl A) 2006. Abstract L48
[63]
Hansen, K.B.; Rosenkilde, M.M.; Knop, F.K.; Wellner, N.; Diep, T.A.; Rehfeld, J.F.; Andersen, U.B.; Holst, J.J.; Hansen, H.S. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J. Clin. Endocrinol. Metab., 2011, 96, E1409-E1417.
[64]
Soga, T.; Ohishi, T.; Matsui, T.; Saito, T.; Matsumoto, M.; Takasaki, J.; Matsumoto, S.; Kamohara, M.; Hiyama, H.; Yoshida, S.; Momose, K.; Ueda, Y.; Matsushime, H.; Kobori, M.; Furuichi, K. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun., 2005, 326, 744-751.
[65]
Morales, P.; Reggio, P.H. An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Cannabis Cannabinoid Res., 2017, 2, 265-273.
[66]
Pertwee, R.G.; Howlett, A.C.; Abood, M.E.; Alexander, S.P.; Di Marzo, V.; Elphick, M.R.; Greasley, P.J.; Hansen, H.S.; Kunos, G.; Mackie, K.; Mechoulam, R.; Ross, R.A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2). Pharmacol. Rev., 2010, 62, 588-631.
[67]
Tanaka, S.; Ishii, K.; Kasai, K.; Yoon, S.O.; Saeki, Y. Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowth. J. Biol. Chem., 2007, 282, 10506-10515.
[68]
Laun, A.S.; Song, Z.H. GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem. Biophys. Res. Commun., 2017, 490, 17-21.
[69]
Yin, H.; Chu, A.; Li, W.; Wang, B.; Shelton, F.; Otero, F.; Nguyen, D.G.; Caldwell, J.S.; Chen, Y.A. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J. Biol. Chem., 2009, 284, 12328-12338.
[70]
Lagerstrom, M.C.; Schioth, H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov., 2008, 7, 339-357.
[71]
Christopoulos, A.; Changeux, J.P.; Catterall, W.A.; Fabbro, D.; Burris, T.P.; Cidlowski, J.A.; Olsen, R.W.; Peters, J.A.; Neubig, R.R.; Pin, J.P.; Sexton, P.M.; Kenakin, T.P.; Ehlert, F.J.; Spedding, M.; Langmead, C.J. International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: Recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol. Rev., 2014, 66, 918-947.
[72]
Pertwee, R.G. Endocannabinoids and Their Pharmacological Actions. Handb. Exp. Pharmacol., 2015, 231, 1-37.
[73]
Pertwee, R.G. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos. Trans. R. Soc. Lond. B Biol. Sci., 2012, 367, 3353-3363.
[74]
Hutcheson, D.M.; Tzavara, E.T.; Smadja, C.; Valjent, E.; Roques, B.P.; Hanoune, J.; Maldonado, R. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br. J. Pharmacol., 1998, 125, 1567-1577.
[75]
Price, M.R.; Baillie, G.L.; Thomas, A.; Stevenson, L.A.; Easson, M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker, G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; Christopoulos, A.; Pertwee, R.G.; Ross, R.A. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol., 2005, 68, 1484-1495.
[76]
Morales, P.; Goya, P.; Jagerovic, N.; Hernandez-Folgado, L. Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review. Cannabis Cannabinoid Res., 2016, 1, 22-30.
[77]
Horswill, J.G.; Bali, U.; Shaaban, S.; Keily, J.F.; Jeevaratnam, P.; Babbs, A.J.; Reynet, C.; Wong Kai In, P. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br. J. Pharmacol., 2007, 152, 805-814.
[78]
Baillie, G.L.; Horswill, J.G.; Anavi-Goffer, S.; Reggio, P.H.; Bolognini, D.; Abood, M.E.; McAllister, S.; Strange, P.G.; Stephens, G.J.; Pertwee, R.G.; Ross, R.A. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol. Pharmacol., 2013, 83, 322-338.
[79]
Ahn, K.H.; Mahmoud, M.M.; Samala, S.; Lu, D.; Kendall, D.A. Profiling two indole-2-carboxamides for allosteric modulation of the CB1 receptor. J. Neurochem., 2013, 124, 584-589.
[80]
Mahmoud, M.M.; Ali, H.I.; Ahn, K.H.; Damaraju, A.; Samala, S.; Pulipati, V.K.; Kolluru, S.; Kendall, D.A.; Lu, D. Structure-activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1). J. Med. Chem., 2013, 56, 7965-7975.
[81]
Khurana, L.; Ali, H.I.; Olszewska, T.; Ahn, K.H.; Damaraju, A.; Kendall, D.A.; Lu, D. Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1). J. Med. Chem., 2014, 57, 3040-3052.
[82]
Hind, W.H.; England, T.J.; O’Sullivan, S.E. Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARgamma and 5-HT1A receptors. Br. J. Pharmacol., 2016, 173, 815-825.
[83]
McPartland, J.M.; Duncan, M.; Di Marzo, V.; Pertwee, R.G. Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br. J. Pharmacol., 2015, 172, 737-753.
[84]
Laprairie, R.B.; Bagher, A.M.; Kelly, M.E.; Denovan-Wright, E.M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol., 2015, 172, 4790-4805.
[85]
Petrucci, V.; Chicca, A.; Glasmacher, S.; Paloczi, J.; Cao, Z.; Pacher, P.; Gertsch, J. Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage. Sci. Rep., 2017, 7, 9560.
[86]
Soethoudt, M.; Grether, U.; Fingerle, J.; Grim, T.W.; Fezza, F.; de Petrocellis, L.; Ullmer, C.; Rothenhausler, B.; Perret, C.; van Gils, N.; Finlay, D.; MacDonald, C.; Chicca, A.; Gens, M.D.; Stuart, J.; de Vries, H.; Mastrangelo, N.; Xia, L.; Alachouzos, G.; Baggelaar, M.P.; Martella, A.; Mock, E.D.; Deng, H.; Heitman, L.H.; Connor, M. Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat. Commun., 2017, 8, 13958.
[87]
Landomiel, F.; Gallay, N.; Jegot, G.; Tranchant, T.; Durand, G.; Bourquard, T.; Crepieux, P.; Poupon, A.; Reiter, E. Biased signalling in follicle stimulating hormone action. Mol. Cell. Endocrinol., 2014, 382, 452-459.
[88]
Kenakin, T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci., 1995, 16, 232-238.
[89]
Violin, J.D.; Lefkowitz, R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci., 2007, 28, 416-422.
[90]
Glass, M.; Northup, J.K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol., 1999, 56, 1362-1369.
[91]
Bosier, B.; Hermans, E.; Lambert, D. Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor. Br. J. Pharmacol., 2008, 155, 24-33.
[92]
Bosier, B.; Tilleux, S.; Najimi, M.; Lambert, D.M.; Hermans, E. Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. J. Neurochem., 2007, 102, 1996-2007.
[93]
Maneuf, Y.P.; Brotchie, J.M. Paradoxical action of the cannabinoid WIN 55, 212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br. J. Pharmacol., 1997, 120, 1397-1398.
[94]
Franks, L.N.; Ford, B.M.; Madadi, N.R.; Penthala, N.R.; Crooks, P.A.; Prather, P.L. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. Eur. J. Pharmacol., 2014, 737, 140-148.
[95]
Ford, B.M.; Franks, L.N.; Tai, S.; Fantegrossi, W.E.; Stahl, E.L.; Berquist, M.D.; Cabanlong, C.V.; Wilson, C.D.; Penthala, N.R.; Crooks, P.A.; Prather, P.L. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development. Pharmacol. Res., 2017, 125, 161-177.
[96]
Ahn, K.H.; Mahmoud, M.M.; Kendall, D.A. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J. Biol. Chem., 2012, 287, 12070-12082.
[97]
Ahn, K.H.; Mahmoud, M.M.; Shim, J.Y.; Kendall, D.A. Distinct roles of beta-arrestin 1 and beta-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J. Biol. Chem., 2013, 288, 9790-9800.
[98]
Raehal, K.M.; Bohn, L.M. beta-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb. Exp. Pharmacol., 2014, 219, 427-443.
[99]
Atwood, B.K.; Wager-Miller, J.; Haskins, C.; Straiker, A.; Mackie, K. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol. Pharmacol., 2012, 81, 250-263.
[100]
Dhopeshwarkar, A.; Mackie, K. Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway. J. Pharmacol. Exp. Ther., 2016, 358, 342-351.
[101]
Pertwee, R.G. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict. Biol., 2008, 13, 147-159.
[102]
Laprairie, R.B.; Bagher, A.M.; Kelly, M.E.; Denovan-Wright, E.M. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease. Mol. Pharmacol., 2016, 89, 364-375.
[103]
Peters, M.F.; Scott, C.W. Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J. Biomol. Screen., 2009, 14, 246-255.
[104]
Breivogel, C.S.; Puri, V.; Lambert, J.M.; Hill, D.K.; Huffman, J.W.; Razdan, R.K. The influence of beta-arrestin2 on cannabinoid CB1 receptor coupling to G-proteins and subcellular localization and relative levels of beta-arrestin1 and 2 in mouse brain. J. Recept. Signal Transduct. Res., 2013, 33, 367-379.
[105]
Chen, X.; Zheng, C.; Qian, J.; Sutton, S.W.; Wang, Z.; Lv, J.; Liu, C.; Zhou, N. Involvement of beta-arrestin-2 and clathrin in agonist-mediated internalization of the human cannabinoid CB2 receptor. Curr. Mol. Pharmacol., 2014, 7, 67-80.
[106]
Howlett, A.C.; Abood, M.E. CB1 and CB2 Receptor Pharmacology. Adv. Pharmacol., 2017, 80, 169-206.
[107]
Scotter, E.L.; Abood, M.E.; Glass, M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br. J. Pharmacol., 2010, 160, 480-498.
[108]
Irannejad, R.; Tomshine, J.C.; Tomshine, J.R.; Chevalier, M.; Mahoney, J.P.; Steyaert, J.; Rasmussen, S.G.; Sunahara, R.K.; El-Samad, H.; Huang, B.; von Zastrow, M. Conformational biosensors reveal GPCR signalling from endosomes. Nature, 2013, 495, 534-538.
[109]
Tsvetanova, N.G.; von Zastrow, M. Spatial encoding of cyclic AMP signaling specificity by GPCR endocytosis. Nat. Chem. Biol., 2014, 10, 1061-1065.
[110]
Godbole, A.; Lyga, S.; Lohse, M.J.; Calebiro, D. Internalized TSH receptors en route to the TGN induce local Gs-protein signaling and gene transcription. Nat. Commun., 2017, 8, 443.
[111]
Irannejad, R.; Pessino, V.; Mika, D.; Huang, B.; Wedegaertner, P.B.; Conti, M.; von Zastrow, M. Functional selectivity of GPCR-directed drug action through location bias. Nat. Chem. Biol., 2017, 13, 799-806.
[112]
Boivin, B.; Vaniotis, G.; Allen, B.G.; Hebert, T.E. G protein-coupled receptors in and on the cell nucleus: a new signaling paradigm? J. Recept. Signal Transduct. Res., 2008, 28, 15-28.
[113]
Revankar, C.M.; Cimino, D.F.; Sklar, L.A.; Arterburn, J.B.; Prossnitz, E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307, 1625-1630.
[114]
Suofu, Y.; Li, W.; Jean-Alphonse, F.G.; Jia, J.Y.; Khattar, N.K.; Li, J.T.; Baranov, S.V.; Leronni, D.; Mihalik, A.C.; He, Y.Q.; Cecon, E.; Wehbi, V.L.; Kim, J.; Heath, B.E.; Baranova, O.V.; Wang, X.M.; Gable, M.J.; Kretz, E.S.; Di Benedetto, G.; Lezon, T.R.; Ferrando, L.M.; Larkin, T.M.; Sullivan, M.; Yablonska, S.; Wang, J.J.; Minnigh, M.B.; Guillaumet, G.; Suzenet, F.; Richardson, R.M.; Poloyac, S.M.; Stolz, D.B.; Jockers, R.; Witt-Enderby, P.A.; Carlisle, D.L.; Vilardaga, J.P.; Friedlander, R.M. Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. Proc. Natl. Acad. Sci. USA, 2017, 114, E7997-E8006.
[115]
Marsicano, G.; Lutz, B. Neuromodulatory functions of the endocannabinoid system. J. Endocrinol. Invest., 2006, 29, 27-46.
[116]
Bartova, A.; Birmingham, M.K. Effect of delta9-tetrahydrocannabinol on mitochondrial NADH-oxidase activity. J. Biol. Chem., 1976, 251, 5002-5006.
[117]
Tedesco, L.; Valerio, A.; Dossena, M.; Cardile, A.; Ragni, M.; Pagano, C.; Pagotto, U.; Carruba, M.O.; Vettor, R.; Nisoli, E. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes, 2010, 59, 2826-2836.
[118]
Aquila, S.; Guido, C.; Santoro, A.; Perrotta, I.; Laezza, C.; Bifulco, M.; Sebastiano, A. Human sperm anatomy: Ultrastructural localization of the cannabinoid1 receptor and a potential role of anandamide in sperm survival and acrosome reaction. Anat. Rec. (Hoboken), 2010, 293, 298-309.
[119]
Benard, G.; Massa, F.; Puente, N.; Lourenco, J.; Bellocchio, L.; Soria-Gomez, E.; Matias, I.; Delamarre, A.; Metna-Laurent, M.; Cannich, A.; Hebert-Chatelain, E.; Mulle, C.; Ortega-Gutierrez, S.; Martin-Fontecha, M.; Klugmann, M.; Guggenhuber, S.; Lutz, B.; Gertsch, J.; Chaouloff, F.; Lopez-Rodriguez, M.L.; Grandes, P.; Rossignol, R.; Marsicano, G. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat. Neurosci., 2012, 15, 558-564.
[120]
Hebert-Chatelain, E.; Desprez, T.; Serrat, R.; Bellocchio, L.; Soria-Gomez, E.; Busquets-Garcia, A.; Pagano Zottola, A.C.; Delamarre, A.; Cannich, A.; Vincent, P.; Varilh, M.; Robin, L.M.; Terral, G.; Garcia-Fernandez, M.D.; Colavita, M.; Mazier, W.; Drago, F.; Puente, N.; Reguero, L.; Elezgarai, I.; Dupuy, J.W.; Cota, D.; Lopez-Rodriguez, M.L.; Barreda-Gomez, G.; Massa, F.; Grandes, P.; Benard, G.; Marsicano, G. A cannabinoid link between mitochondria and memory. Nature, 2016, 539, 555-559.
[121]
Bosier, B.; Bellocchio, L.; Metna-Laurent, M.; Soria-Gomez, E.; Matias, I.; Hebert-Chatelain, E.; Cannich, A.; Maitre, M.; Leste-Lasserre, T.; Cardinal, P.; Mendizabal-Zubiaga, J.; Canduela, M.J.; Reguero, L.; Hermans, E.; Grandes, P.; Cota, D.; Marsicano, G. Astroglial CB1 cannabinoid receptors regulate leptin signaling in mouse brain astrocytes. Mol. Metab., 2013, 2, 393-404.
[122]
Gutierrez-Rodriguez, A.; Bonilla-Del Rio, I.; Puente, N.; Gomez-Urquijo, S.M.; Fontaine, C.J.; Egana-Huguet, J.; Elezgarai, I.; Ruehle, S. Localization of the cannabinoid type-1 receptor in subcellular astrocyte compartments of mutant mouse hippocampus. Glia, 2018, 66(7), 1417-1431.
[123]
Brailoiu, G.C.; Deliu, E.; Marcu, J.; Hoffman, N.E.; Console-Bram, L.; Zhao, P.; Madesh, M.; Abood, M.E.; Brailoiu, E. Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry, 2014, 53, 4990-4999.
[124]
Hebert-Chatelain, E.; Reguero, L.; Puente, N.; Lutz, B.; Chaouloff, F.; Rossignol, R.; Piazza, P.V.; Benard, G.; Grandes, P.; Marsicano, G. Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor. Mol. Metab., 2014, 3, 495-504.
[125]
den Boon, F.S.; Chameau, P.; Schaafsma-Zhao, Q.; van Aken, W.; Bari, M.; Oddi, S.; Kruse, C.G.; Maccarrone, M.; Wadman, W.J.; Werkman, T.R. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc. Natl. Acad. Sci. USA, 2012, 109, 3534-3539.
[126]
Currie, S.; Rainbow, R.D.; Ewart, M.A.; Kitson, S.; Pliego, E.H.; Kane, K.A.; McCarron, J.G. IP(3)R-mediated Ca(2+) release is modulated by anandamide in isolated cardiac nuclei. J. Mol. Cell. Cardiol., 2008, 45, 804-811.
[127]
Krishna Kumar, K.; Shalev-Benami, M.; Robertson, M.J.; Hu, H.; Banister, S.D.; Hollingsworth, S.A.; Latorraca, N.R.; Kato, H.E.; Hilger, D.; Maeda, S.; Weis, W.I.; Farrens, D.L.; Dror, R.O.; Malhotra, S.V.; Kobilka, B.K.; Skiniotis, G. Structure of a signaling cannabinoid receptor 1-g protein complex. Cell, 2019, 176, 448-458.
[128]
Li, X.T.; Hua, T.; Vemuri, K.; Ho, J.H.; Wu, Y.R.; Wu, L.J.; Popov, P.; Benchama, O.; Zvonok, N.; Locke, K.; Qu, L.; Han, G.W.; Iyer, M.R.; Cinar, R.; Coffey, N.J.; Wang, J.J.; Wu, M.; Katritch, V.; Zhao, S.W.; Kunos, G.; Bohn, L.M.; Makriyannis, A.; Stevens, R.C.; Liu, Z.J. Crystal structure of the human cannabinoid receptor cb2. Cell, 2019, 176, 459-467.
Related Journals
Related Books
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Biologically Active Natural Products from Asia and Africa: A Selection of Topics
Article Metrics
132
29
2
1